File Copy
09/870,937
updated

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 130470

TO: David Lamberston Location: REM-2B79/2C70 Art Unit: 1636 Tuesday, April 12, 2005 Case Serial Number: 09/870937	From: Paul Schulwitz Location: Biotech-Chem Library REM-1A65 Phone: 571-272-2527 paul.schulwitz@uspto.gov

Search Notes

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 12, 2005, 09:00:42 ; Search time 0.001 Seconds
(without alignments)
2.850 Million cell updates/sec

Title: us-09-870-937-1
Perfect score: 25
Sequence: 1 gaggtccctgtgagcatagccctgg 25

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 3 seqs, 57 residues

Total number of hits satisfying chosen parameters: 6

Minimum DB seq length: 15
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		25	100.0	25	1	AX358292	ACCESSION:AX358292
c 2		12.8	51.2	17	1	BD254497	ACCESSION:BD254497
c 3		11.4	45.6	15	1	AX377178	ACCESSION:AX377178
c 4		6	24.0	25	1	AX358292	ACCESSION:AX358292
5		5.8	23.2	15	1	AX377178	ACCESSION:AX377178
6		4.4	17.6	17	1	BD254497	ACCESSION:BD254497

ALIGNMENTS

RESULT 1
AX358292
LOCUS AX358292 25 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 1 from Patent WO0191739.
ACCESSION AX358292
VERSION AX358292.1 GI:18674946
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Wu,B., Seeley,T.W. and Williams,L.T.
TITLE Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
JOURNAL Patent: WO 0191739-A 1 06-DEC-2001;
CHIRON CORPORATION (US)
FEATURES Location/Qualifiers
source 1. .25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense Oligonucleotide"

Query Match 100.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAGGTCCCTGTGAGCATAGCCCTGG 25
||||||||||||||||||||||||||
Db 1 GAGGTCCCTGTGAGCATAGCCCTGG 25

RESULT 2
BD254497/c
LOCUS BD254497 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254497
VERSION BD254497.1 GI:33064267
KEYWORDS JP 2002541795-A/2290.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2290 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2290
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH Key Location/Qualifiers
FT source 1. .17
FT /organism='Eukaryote'.
FEATURES Location/Qualifiers
source 1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 51.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 GTCCCTGTGAGCATAG 19
| |||||||||||| |
Db 17 GGCCCTGTGAGCATCG 2

RESULT 3
AX377178/c
LOCUS AX377178 15 bp DNA linear PAT 18-MAR-2002
DEFINITION Sequence 23 from Patent WO0212342.
ACCESSION AX377178
VERSION AX377178.1 GI:19573468
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kazemi,A., Koshy,B. and Sanchis,A.
TITLE Haplotypes of the edg4 gene
JOURNAL Patent: WO 0212342-A 23 14-FEB-2002;

OM nucleic - nucleic search, using sw model

Run on: April 12, 2005, 09:01:05 ; Search time 0.001 Seconds
(without alignments)
2.850 Million cell updates/sec

Title: us-09-870-937-1
Perfect score: 25
Sequence: 1 gaggtccctgtgagcatagccctgg 25

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 3 seqs, 57 residues

Total number of hits satisfying chosen parameters: 6

Minimum DB seq length: 15
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	25	100.0	25	1	AAI72242	Antisense oligonuc
c 2	12.8	51.2	17	1	AAF02299	Hammerhead ribozym
c 3	11.4	45.6	15	1	ABK46589	EDG4 gene, allele
c 4	6	24.0	25	1	AAI72242	Antisense oligonuc
5	5.8	23.2	15	1	ABK46589	EDG4 gene, allele
6	4.4	17.6	17	1	AAF02299	Hammerhead ribozym

ALIGNMENTS

RESULT 1
AAI72242
ID AAI72242 standard; DNA; 25 BP.
XX
AC AAI72242;
XX
DT 02-APR-2002 (first entry)
XX
DE Antisense oligonucleotide KIA175-545.
XX
KW Antisense; KIAA0175; inhibitor; tumour; P21; P53; chemosensitivity;
KW radiosensitivity; gamma-irradiation; hydroxy urea; cell cycle arrest;
KW sensitization; neoplastic disease; chemotherapy; radiotherapy; cancer;
KW ss.
XX
OS Synthetic.
XX
PN WO200191739-A2.
XX
PD 06-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US017644.
XX
PR 31-MAY-2000; 2000US-0208435P.
XX
PA (CHIR) CHIRON CORP.
XX
PI Wu B, Seeley TW, Williams LT;
XX
DR WPI; 2002-122034/16.
XX
PT New isolated specific inhibitor useful for decreasing the expression of
PT the inhibitor in a mammalian cell.
XX
PS Claim 5; Page 39; 60pp; English.
XX
CC The sequences given in AAI72242-49 are antisense oligonucleotides which
CC were tested to observe their effect on the kinetics of KIAA0175
CC transcript. Inhibitors of KIAA0175 may be used for decreasing the
CC expression of KIAA0175 in mammalian cell (preferably tumour cell). They
CC may also be used for decreasing the expression of P21 and P53 in a
CC mammalian cell, for increasing the chemosensitivity and/or
CC radiosensitivity of a mammalian cell by measuring a reduction in gamma-
CC irradiation or hydroxy urea induced P53 or P21 protein levels measuring a
CC reduction in gamma-irradiation or hydroxy urea induced cell cycle arrest
CC and measuring an increase in gamma-irradiation or hydroxy urea induced
CC cell sensitization, and for treating neoplastic disease in a mammal. The
CC inhibitor provides beneficial improvement of chemo and/or radiotherapy
CC despite low transfection efficiency (10 - 70%) and/or transient gene
CC expression. The inhibitor decreases the side effects of the cancer
CC therapy
XX
SQ Sequence 25 BP; 4 A; 7 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 100.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAGGTCCCTGTGAGCATAGCCCTGG 25
||||||||||||||||||||||||||
Db 1 GAGGTCCCTGTGAGCATAGCCCTGG 25

RESULT 2
AAF02299/c
ID AAF02299 standard; DNA; 17 BP.
XX
AC AAF02299;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #594.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 12, 2005, 09:01:32 ; Search time 0.001 Seconds
(without alignments)
3.250 Million cell updates/sec

Title: us-09-870-937-1
Perfect score: 25
Sequence: 1 gaggtccctgtgagcatagccctgg 25

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 3 seqs, 65 residues

Total number of hits satisfying chosen parameters: 6

Minimum DB seq length: 15
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	25	100.0	25	1	US-09-870-937-1	Sequence 1, Appli
2	16	64.0	20	1	US-10-776-013-60	Sequence 60, Appl
3	16	64.0	20	1	US-10-776-013-61	Sequence 61, Appl
c 4	6	24.0	25	1	US-09-870-937-1	Sequence 1, Appli
c 5	4.8	19.2	20	1	US-10-776-013-60	Sequence 60, Appl
c 6	4.6	18.4	20	1	US-10-776-013-61	Sequence 61, Appl

ALIGNMENTS

RESULT 1
US-09-870-937-1
; Sequence 1, Application US/09870937
; Patent No. US20020049180A1
; GENERAL INFORMATION:
; APPLICANT: Wu, Bin
; APPLICANT: Seeley, Todd
; APPLICANT: Williams, Lewis T.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE USING
; TITLE OF INVENTION: CHEMOTHERAPY AND RADIATION SENSITIZERS
; FILE REFERENCE: 200130.514/PP-01623.002
; CURRENT APPLICATION NUMBER: US/09/870,937
; CURRENT FILING DATE: 2001-05-30
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-870-937-1

Query Match 100.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GAGGTCCCTGTGAGCATAGCCCTGG 25
              |||||||||||||||||||||||||
Db          1 GAGGTCCCTGTGAGCATAGCCCTGG 25
```

RESULT 2
US-10-776-013-60
; Sequence 60, Application US/10776013
; Publication No. US20040226056A1
; GENERAL INFORMATION:
; APPLICANT: MYRIAD GENETICS, INC.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Bartel, Paul
; APPLICANT: Heichman, Karen
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 1600.24
; CURRENT APPLICATION NUMBER: US/10/776,013
; CURRENT FILING DATE: 2004-02-09
; PRIOR APPLICATION NUMBER: 09/948904
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 09/466139
; PRIOR FILING DATE: 1999-12-21
; PRIOR APPLICATION NUMBER: 60/113534
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/124120
; PRIOR FILING DATE: 1999-03-12
; PRIOR APPLICATION NUMBER: 60/141243
; PRIOR FILING DATE: 1999-06-30
; PRIOR APPLICATION NUMBER: 09/975072
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/240790
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 10/194967
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/304775
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 695
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-776-013-60

Query Match 64.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          9 TGTGAGCATAGCCCTG 24
              ||||||||||||||||
Db          3 TGTGAGCATAGCCCTG 18
```

RESULT 3
US-10-776-013-61
; Sequence 61, Application US/10776013
; Publication No. US20040226056A1
; GENERAL INFORMATION:
; APPLICANT: MYRIAD GENETICS, INC.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Bartel, Paul
; APPLICANT: Heichman, Karen
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 1600.24
; CURRENT APPLICATION NUMBER: US/10/776,013
; CURRENT FILING DATE: 2004-02-09